Sector Expert: Neil Maruoka

Canaccord Genuity

Neil joined the Life Sciences team at Canaccord in 2006 after several years in the biotechnology sector. Prior, Neil worked as an associate analyst covering both small and large-cap biotech and pharmaceutical companies. Neil began his career as an Investment Analyst at MDS Capital, one of the largest biotechnology-focused venture capital management firms in Canada. Neil graduated with an undergraduate degree in Life Sciences and a Masters degree in Physiology and Molecular Biology from Queen's University in Kingston, Ontario. He also holds an MBA from the Richard Ivey School of Business at the University of Western Ontario.



Recent Quotes

"HLTH has indicated that it continues to pursue additional accretive acquisitions."

— Neil Maruoka, Canaccord Genuity (8/2/16)
more >

"We are initiating coverage of HLTH with a Buy rating;we see upside to our valuation with further Athas-generated organic growth, and future accretive acquisitions of surgical facilities."

— Neil Maruoka, Canaccord Genuity (7/13/16)
more >

"ONCY's phase 3 study results should be a major milestone for the stock."

— Neil Maruoka, Canaccord Genuity (10/2/13)
more >

"ONCY reported positive response rate data from its phase 2 study of Reolysin."

— Neil Maruoka, Canaccord Genuity (9/9/13)
more >

"ONCY's burn rate has dropped substantially, and it has adequate cash on hand."

— Neil Maruoka, Canaccord Genuity (8/1/13)
more >

"Based on recent evidence of efficacy for Reolysin, we would be buyers of ONC stock."

— Neil Maruoka, Canaccord Genuity (5/9/13)
more >

"We anticipate more impactful data from ONCY's Reolysin trial."

— Neil Maruoka, Canaccord Genuity (3/15/13)
more >

"ONCY's phase 2, Reolysin study results look to be exceptional."

— Neil Maruoka, Canaccord Genuity (2/8/13)
more >



Due to permission requirements, not all quotes are shown.